Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$5.52
$4.78
$1.58
$7.27
$492.06M-0.591.20 million shs890,299 shs
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
$14.30
-1.4%
$16.54
$3.18
$21.48
$383.50M1.28224,020 shs783,627 shs
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
$10.37
-3.3%
$10.38
$4.81
$27.50
$346.61MN/A249,569 shs123,059 shs
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
$1.10
$1.09
$0.26
$1.28
$116.26M1.61957,342 shsN/A
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
0.00%+3.56%+22.12%+52.07%+222.81%
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
0.00%-15.08%-27.41%-8.22%+293.94%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
0.00%-8.80%-2.63%+19.20%+1,036,999,900.00%
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
4.1219 of 5 stars
4.63.00.00.01.94.21.3
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
2.2958 of 5 stars
3.53.00.00.02.20.80.6
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
2.015 of 5 stars
3.50.00.00.00.03.30.6
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
3.11
Buy$9.8378.14% Upside
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
3.00
Buy$29.67107.46% Upside
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
3.00
Buy$37.50261.62% Upside
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SCTL, ETON, MBX, and AMLX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/30/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
5/29/2025
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$33.00 ➝ $35.00
5/16/2025
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$24.00 ➝ $26.00
5/14/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$7.00 ➝ $8.00
5/14/2025
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$26.00 ➝ $28.00
5/9/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $16.00
5/7/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$4.00 ➝ $10.00
5/6/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
4/10/2025
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$38.00
4/10/2025
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$44.00 ➝ $44.00
4/10/2025
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Outperform$38.00
(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$1.27M-386.84$1.00 per share5.51$6.42 per share0.86
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
$48.33M7.94$0.00 per share4,502.79$0.60 per share23.83
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/AN/AN/AN/A
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
$94.64M1.23N/AN/A$0.56 per share1.96
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$49.27M-$3.11N/AN/AN/AN/A-36.97%-29.61%8/6/2025 (Estimated)
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
-$940K-$0.18N/A28.60N/A-15.81%-36.29%-16.84%8/4/2025 (Estimated)
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
-$13.27M-$0.15N/AN/A-14.03%-23.82%-8.80%N/A

Latest SCTL, ETON, MBX, and AMLX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
$0.09$0.07-$0.02-$0.06$14.33 million$17.28 million
5/8/2025Q1 2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$0.45-$0.42+$0.03-$0.42N/AN/A
3/18/2025Q4 2024
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
-$0.02-$0.02N/A-$0.02$10.53 million$11.65 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$1.0218.41%N/AN/A N/A
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
N/AN/AN/AN/AN/A
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/AN/AN/A
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/A
4.55
4.55
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
N/A
1.51
1.41
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/A
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
0.01
1.07
0.86

Institutional Ownership

CompanyInstitutional Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
95.84%
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
27.86%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/A
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
87.15%

Insider Ownership

CompanyInsider Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
11.70%
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
16.03%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
52.19%
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
20089.14 million60.53 millionOptionable
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
2026.82 million22.17 millionOptionable
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
3633.42 millionN/AN/A
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
258105.69 million97.66 millionOptionable

Recent News About These Companies

About | Societal Experts Action Network
Why Is Societal CDMO (SCTL) Stock Up 133% Today?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amylyx Pharmaceuticals stock logo

Amylyx Pharmaceuticals NASDAQ:AMLX

$5.52 0.00 (0.00%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$5.51 -0.01 (-0.18%)
As of 06/13/2025 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Eton Pharmaceuticals stock logo

Eton Pharmaceuticals NASDAQ:ETON

$14.30 -0.21 (-1.45%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$14.44 +0.15 (+1.01%)
As of 06/13/2025 05:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

MBX Biosciences stock logo

MBX Biosciences NYSE:MBX

$10.37 -0.35 (-3.26%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$10.36 -0.01 (-0.09%)
As of 06/13/2025 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Societal CDMO stock logo

Societal CDMO NASDAQ:SCTL

Societal CDMO, Inc., a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecules in the United States and internationally. The company provides end-to-end services, such as formulation development focusing on complex formulations, reformulation, physical characterization, and excipient compatibility; analytical methods development which offers a range of analytical testing capabilities, including product testing, ICH stability, method development and validation, chromatography and spectroscopy equipment, stability chambers, and microbial testing; and pharmaceutical manufacturing that provides milling, blending, compression, spray and rotary granulation, particle and bead coating, encapsulation, liquids, lyophilization, and sterile fill and finish services. It also offers regulatory support, including handling communications with the food and drug administration (FDA) and seek consultation and guidance for client FDA meetings and responses; and pharmaceutical packaging and logistics, as well as smaller-scale primary and secondary packaging, labeling and kitting options suited for clinical trial materials and development packaging needs across dosage forms. The company was formerly known as Recro Pharma, Inc. and changed its name to Societal CDMO, Inc. in March 2022. Societal CDMO, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.